IFM Investors Pty Ltd Sells 256 Shares of DaVita Inc. (NYSE:DVA)

IFM Investors Pty Ltd lessened its stake in shares of DaVita Inc. (NYSE:DVA) by 1.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,658 shares of the company’s stock after selling 256 shares during the quarter. IFM Investors Pty Ltd’s holdings in DaVita were worth $2,024,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Deutsche Bank AG raised its position in DaVita by 421.8% in the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares during the last quarter. 8 Knots Management LLC bought a new position in DaVita in the 4th quarter valued at $89,504,000. Doma Perpetual Capital Management LLC bought a new position in DaVita in the 4th quarter valued at $53,076,000. Norges Bank bought a new position in DaVita in the 4th quarter valued at $36,626,000. Finally, Invesco Ltd. raised its position in DaVita by 21.3% in the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 0.6 %

Shares of DaVita stock traded up $0.74 during trading on Friday, reaching $133.51. 477,673 shares of the company were exchanged, compared to its average volume of 478,110. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $141.54. The business has a 50-day moving average price of $132.12 and a 200-day moving average price of $110.85. The firm has a market capitalization of $11.71 billion, a price-to-earnings ratio of 18.04, a P/E/G ratio of 1.19 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. DaVita had a return on equity of 64.42% and a net margin of 5.70%. The business had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. During the same period in the previous year, the firm earned $1.11 earnings per share. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. Sell-side analysts anticipate that DaVita Inc. will post 9.23 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Truist Financial lifted their price objective on DaVita from $130.00 to $135.00 and gave the company a “hold” rating in a research report on Tuesday, February 20th. UBS Group boosted their target price on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. Finally, Barclays started coverage on DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 target price for the company. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, DaVita presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the completion of the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 29,488 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $119.81, for a total value of $3,532,957.28. Following the completion of the transaction, the chief operating officer now directly owns 37,687 shares of the company’s stock, valued at $4,515,279.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 134,540 shares of company stock valued at $16,551,071. Company insiders own 1.40% of the company’s stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.